Hikma appoints new CEO

Hikma Pharmaceuticals Plc
23 April 2007




  Hikma announces the appointment of Said Darwazah as Chief Executive Officer

LONDON, 23 April 2007 - The Board of Hikma Pharmaceuticals PLC ('Hikma') (LSE:
HIK) (DIFX: HIK), the multinational pharmaceuticals group, announces changes to
its senior management team.

Said Darwazah is appointed as Chief Executive Officer with effect from 1 July
2007. Samih Darwazah, Hikma's current Chairman and Chief Executive Officer will
continue in both positions until July, when he will assume the role of
Non-Executive Chairman. 'Said's proven abilities to expand both the top and
bottom lines will be invaluable and will enable Hikma to continue to deliver on
its promises, as it has for years past,' said Samih Darwazah. 'We are very
excited to have Said at the helm during this important growth period for Hikma.'

Said, 49, was most recently Minister of Health in the Hashemite Kingdom of
Jordan, a post which he held from 2003 until 2006.

From 1994 until 2003, Said was Chairman and CEO of Hikma Investment Company,
then the holding company for the Hikma group. During his tenure at Hikma, Said
led the Company through significant change and achievement. Key milestones
include the acquisition, integration and turnaround of West-ward Pharmaceuticals
in the US and the greenfield development of the Injectables business in Europe
and the MENA region. Under his leadership, the Company's facilities in Jordan,
the US and Portugal were inspected and approved by the FDA.

Said is currently on the Board of Directors of the Central Bank of Jordan and
the King Hussein Cancer Institute. He has a degree in industrial engineering
from Purdue University in the US and an MBA from INSEAD.

Sir David Rowe-Ham, Senior independent Non-Executive Director and Chairman of
the Nomination Committee said, 'We are delighted to welcome Said back as Hikma's
Chief Executive. His significant operational experience and extensive knowledge
of the MENA region and its key pharmaceutical markets, combined with his
experience in the United States, will complement the skills of our existing
team, and will add greatly to the future success of Hikma.'

Said Darwazah said, 'I am very pleased to be taking up the role of Chief
Executive at what is a very exciting time for the Company. The opportunities for
Hikma are considerable and I look forward to working with my colleagues to
continue to grow the business and enhance shareholder value.'

Said was previously a director of Capital Bank of Jordan. There are no other
details in respect of this appointment that are relevant to be disclosed
pursuant to the Listing Rules of the Financial Services Authority.

                                    - ENDS -
Enquiries:

Hikma Pharmaceuticals PLC
Susan Ringdal                                     [phone]
Investor Relations Director

Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed          [phone]

About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the Middle East and
North Africa ('MENA') region, the United States and Europe. In 2006, the Group
had revenue of $317 million and profit attributable to shareholders of $55
million. At 31 December 2006, the Group had over 2,443 employees. For news and
other information, please visit www.hikma.com.

Other regulatory disclosures
In accordance with the Offered Securities Rules of the Dubai Financial Services
Authority, Hikma discloses that Said Darwazah was selected by the Company's
Nomination Committee.




                      This information is provided by RNS
            The company news service from the London Stock Exchange